Grifols stock: fundamental analysis
Stocks · GRF · Healthcare
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. Below are its fundamentals, explained in the order worth reading them: business quality, debt, growth and, last, whether the price is reasonable.
- Price: 9.54 EUR
- Market cap: 6.5B EUR
Data as of September 18, 2026 · Yahoo Finance
Quick read
Business quality
ROE of 6.9%: a low return on shareholders' money. Out of every 100 in sales, 6.1 end up as profit.
Financial health
Net debt/EBITDA of 5.4x: high leverage; keep an eye on maturities and the cost of debt.
Growth
Revenue is down 0.9% year on year. Earnings are up 32.9%.
Valuation
It trades at a P/E of 14.5, below the 33.9 median of the healthcare companies we track. On expected earnings the P/E falls to 8.4: the market expects profits to rise. A low P/E is not automatically a bargain: it can reflect risks or slower growth.
Dividend
Dividend yield of 0.9% (0.08 EUR per share per year) with a payout ratio of 35.2%.
Tools
All metrics
| Grifols | Sector median | |
|---|---|---|
| Business quality | ||
| ROE | 6.9% | 25.7% |
| ROA | 4.2% | 9.0% |
| Gross margin | 37.8% | 70.5% |
| Operating margin | 15.9% | 28.5% |
| Net margin | 6.1% | 15.6% |
| Financial health | ||
| Net debt/EBITDA | 5.4x | 2.0x |
| Debt/equity | 1.2x | 0.7x |
| Current ratio | 2.4x | 1.3x |
| Growth | ||
| Revenue growth | -0.9% | 10.2% |
| Earnings growth | 32.9% | 139.8% |
| Valuation | ||
| P/E ratio | 14.5x | 33.9x |
| Forward P/E | 8.4x | 16.7x |
| EV/EBITDA | 10.8x | 17.0x |
| Price/book | 1.2x | 4.2x |
| FCF yield | 8.8% | 4.7% |
| Dividend | ||
| Dividend yield | 0.9% | 1.8% |
| Payout ratio | 35.2% | 48.0% |
| Beta (volatility) | 1.2x | 0.3x |
Frequently asked questions
What is Grifols's P/E ratio?
Grifols's P/E is 14.5 based on trailing 12-month earnings and 8.4 on expected earnings. The median for its sector among the companies we track is 33.9. Data as of September 18, 2026.
What dividend does Grifols pay?
Dividend yield of 0.9% (0.08 EUR per share per year) with a payout ratio of 35.2%.
Is Grifols stock expensive?
It trades at a P/E of 14.5, below the 33.9 median of the healthcare companies we track. On expected earnings the P/E falls to 8.4: the market expects profits to rise. A low P/E is not automatically a bargain: it can reflect risks or slower growth. This is an educational reading based on ratios, not a buy or sell recommendation.
Does Grifols have a lot of debt?
Net debt/EBITDA of 5.4x: high leverage; keep an eye on maturities and the cost of debt.
What is Grifols's market cap?
Grifols has a market cap of 6.5B EUR and its shares trade at 9.54 EUR, with a 52-week range of 8.43 EUR to 12.87 EUR (data as of September 18, 2026).
Other companies in the sector
Trailing 12-month metrics. Educational content, not investment advice.